Haleon plc (HLN)vsHarrow Health Inc (HROW)
HLN
Haleon plc
$9.78
+0.72%
HEALTHCARE · Cap: $43.42B
HROW
Harrow Health Inc
$38.45
-8.19%
HEALTHCARE · Cap: $1.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 4005% more annual revenue ($11.03B vs $268.68M). HLN leads profitability with a 15.1% profit margin vs -5.6%. HLN earns a higher WallStSmart Score of 63/100 (C+).
HLN
Buy63
out of 100
Grade: C+
HROW
Avoid17
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
No standout strengths identified
Areas to Watch
0.6% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Smaller company, higher risk/reward
Trading at 49.9x book value
ROE of -35.4% — below average capital efficiency
Revenue declined 7.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : HROW
HROW has a balanced fundamental profile.
Bear Case : HLN
The primary concerns for HLN are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : HROW
The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 10.47 is elevated, increasing financial risk.
Key Dynamics to Monitor
HLN profiles as a value stock while HROW is a turnaround play — different risk/reward profiles.
HROW carries more volatility with a beta of 0.26 — expect wider price swings.
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (63/100 vs 17/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global consumer health company formed from a spin-off of GlaxoSmithKline, focusing on delivering innovative health solutions across a diverse portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. By concentrating on key segments such as oral care, pain relief, and dietary supplements, Haleon effectively addresses the dynamic needs of consumers while capitalizing on strong brand equity. The company's dedication to sustainability and relentless innovation, combined with strategic investments in product development, positions it advantageously for sustained long-term growth, thereby enhancing health outcomes and maximizing shareholder value.
Visit Website →Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?